MiMedx Announces Organizational Realignment Program
Friday, December 07, 2018 10:57 AM
Plan Will Improve Cost Structure and is Designed to Position Business for Long-Term Success

MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced its plans to implement a broad-based organizational realignment, cost reduction and efficiency program to better ensure the Company's cost structure is appropriate given its revenue expectations. MiMedx plans to execute these initiatives while continuing to deliver products and support for healthcare providers and the patients they serve. 

"Today's announcement is a continuation of management's efforts to position the business for long-term success by focusing on our wound care business, where our clinical studies best support patient outcomes and for which reimbursement policy has traditionally been more stable," said David Coles, Interim Chief Executive Officer. "Recent business trends and our internal analysis have led us to simplify and streamline our organizational structure, and reduce costs in order to improve profitability and liquidity."

The Company remains dedicated to executing its long-term strategic plan. In the near term, this includes a sharp focus on its traditional wound care business, further developing the Company's product pipeline, and continuing to pursue FDA approval for micronized dehydrated human amnion/chorion membrane (dHACM) to treat certain musculoskeletal pain indications as MiMedx transitions to a biopharmaceutical company. 

Read more...
 
AdvaMed Statement on ICIJ Medical Device Stories
Monday, November 26, 2018 10:14 AM

Washington, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement on the recent stories from the International Consortium of Investigative Journalists (ICIJ) on the medical technology industry:  

“Every one of us will inevitably face a moment where we will hope for a miracle to make a child, sibling, parent, grandparent or loved one well again. Whether it’s a pacemaker that keeps a heart beating, an implant that allows a child to hear for the first time, or an artificial knee that allows a grandmother to play with her grandkids, medical devices are the foundation of modern medicine, providing physicians and nurses the tools they rely on to improve patient care.       

“Yet, instead of a comprehensive look at both the challenges and the achievements of an industry that touches almost every human life, these stories counterfeit the life-changing and life-saving solutions delivered to billions of people worldwide.  

Read more...
 
GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
Monday, November 19, 2018 09:50 AM

Combined Technologies May Yield Therapies for Multiple Cancer Indications 

ATLANTA, GA, - (NewMediaWire) - November 19, 2018 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with Leidos, Inc. on a research program evaluating the combination of the companies’ respective technologies. The project will include the design, construction, and characterization of multiple immunotherapeutic vaccine candidates using GeoVax’s MVA-VLP vaccine platform combined with certain novel peptide PD-1 checkpoint inhibitors developed by Leidos. The vaccine design, construction, and characterization will be performed at GeoVax with further analysis conducted by Leidos. 
GeoVax’s vaccine technology is based on its live Modified Vaccinia Ankara (MVA) platform, which generates vaccine antigens, in the form of multimeric proteins or noninfectious VLPs, in the individual being vaccinated. Gene sequences of target antigens are inserted into the MVA genome which drives their expression and budding from the infected cells. In this way, vaccination strategy mimics a natural viral infection which induces two pools of proteins – virus-infected cells and released multimeric or VLP proteins.

Read more...
 
Georgia Bio Welcomes Kristina Forbes as Senior Director of Member Engagement
Thursday, November 15, 2018 05:57 PM

The board and staff of Georgia Bio are delighted to announce the newest member of our team: Kristina Forbes, who officially joined Georgia Bio as our full-time Senior Director of Member Engagement.  This newly created role will increase the depth of Georgia Bio’s collaboration with our members as we continue to amplify learning and engagement across our community, and strengthen the voice of life sciences in Georgia.

“Kristina’s role will enable Georgia Bio to keep its finger on the pulse of our growing membership, as we continue to inform and strengthen the voice of Georgia’s innovative biotech, medtech and digital health sectors,” said Maria Thacker Goethe, Georgia Bio’s Acting President and CEO.  “We trust her passion for and commitment to member engagement, community growth, and partner development will serve her well as a member of the Georgia Bio team.” 

Kristina comes to Georgia Bio with a depth of experience in association management and member engagement, in her role as Director of Business Development for the Technology Association of Georgia (TAG).  There, her work focused on expanding the TAG network and onboarding new members. Kristina brings with her a rich background across a spectrum of community engagement initiatives and organizations that we are sure will help to provide more value to members and growth of the sector. 

She achieved her bachelor’s degree in Psychology from the University of Georgia and was raised in Alpharetta. In addition to her work at TAG, Kristina previously worked with the Boy Scouts of America and Chi Phi Educational Trust, bringing more than sixyears of experience in non-profit membership and fundraising. Kristina lives in Midtown Atlanta and has been a volunteer member of Rotary International, Cobb County Chamber of Commerce, Delta Gamma and Children’s Healthcare of Atlanta. In her spare time, she enjoys spending time with her dog and baking apple pies.

Kristina may be reached at [email protected]or 404-920-2043.

 
GeoVax and Virometix to Collaborate on Immunotherapy Program for HPV Infections and Related Cancers
Tuesday, November 13, 2018 01:00 PM

GeoVax Continues Expansion of International Collaborative Efforts for its Unique MVA-VLP Vaccine Technology

Atlanta, GA - (NewMediaWire) - November 13, 2018 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, and Virometix AG, a company developing next-generation Synthetic Virus-Like Particle (SVLPTM) based vaccines, announced today the start of a collaboration to develop a therapeutic vaccine for human papillomavirus (HPV) infection. The collaboration will include preclinical animal testing of GeoVax’s MVA-vectored HPV vaccine candidates in combination with Virometix’ synthetic HPV vaccine candidate.

GeoVax’s vaccine technology is based on its live Modified Vaccinia Ankara (MVA) platform, which generates vaccine antigens, in the form of multimeric proteins or noninfectious VLPs, in the individual being vaccinated. Gene sequences of target antigens are inserted into the MVA genome which drives their expression and budding from the infected cells. In this way, vaccination induces two pools of antigens as targets for the immune response – virus-infected cells and released multimeric or VLP proteins. This strategy mimics a natural viral infection, triggering the body to produce a robust and durable immune response with involvement of both antibodies and T cells.

Read more...
 
<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 6 of 41